Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mannkind's inhaled insulin meets non-inferiority endpoint in Phase III

This article was originally published in Scrip

Executive Summary

Mannkind's Afrezza, an inhaled insulin, was non-inferior to Lilly's Humalog, an injectable fast-acting insulin analogue, when used as an adjunct to Sanofi-Aventis's Lantus (insulin glargine) therapy, show top-line data from a Phase III trial. Mannkind's share price closed up 12% on the news, to $6.25 on Nasdaq, on 10 June 2010.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009120

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel